Calculate the HEART score for chest pain risk stratification in the emergency department. Predicts 6-week major adverse cardiac events (MACE) risk.
The HEART score is a validated clinical decision aid for risk-stratifying patients presenting with chest pain to the emergency department. Developed by Backus et al. in 2008 and validated in the HEART Pathway trial, it evaluates five components: History, ECG, Age, Risk factors, and Troponin to predict the 6-week risk of major adverse cardiac events (MACE) — myocardial infarction, PCI/CABG, or death.
The HEART score excels at identifying truly low-risk patients (score 0-3) who can be safely discharged with outpatient follow-up, reducing unnecessary admissions by 20-30% compared to conventional practice without increasing missed MI rates. At the other extreme, high scores (7-10) identify patients who benefit from urgent invasive evaluation.
The HEART Pathway (serial troponins + HEART score) has been adopted by many emergency departments as a standard chest pain protocol, improving both patient safety and resource utilization. This calculator keeps the scoring logic visible so clinicians can follow the individual components before applying a pathway decision. Check the example with realistic values before reporting.
Chest pain is one of the most common ED presentations (8+ million visits/year in the US), but only 10-15% have acute coronary syndrome. The HEART score safely identifies the ~40% of patients who are truly low-risk, enabling early discharge with outpatient stress testing rather than costly observation stays.
Compared to TIMI and GRACE scores, the HEART score has better sensitivity for detecting low-risk patients and is specifically designed and validated for the undifferentiated ED chest pain population.
HEART = History + ECG + Age + Risk Factors + Troponin History: Slightly suspicious (0), Moderately (1), Highly (2) ECG: Normal (0), Non-specific (1), Significant ST changes (2) Age: <45 (0), 45-64 (1), ≥65 (2) Risk Factors: None (0), 1-2 (1), ≥3 or known atherosclerosis (2) Troponin: Normal (0), 1-3× ULN (1), >3× ULN (2) Total range: 0-10
Result: HEART Score 4 — Moderate Risk
A 60-year-old with moderately suspicious chest pain, non-specific ECG changes, normal troponin, and 1-2 risk factors scores 4 points. This falls in the moderate range (~12-17% MACE). Admission for serial troponins and non-invasive evaluation (stress test or CCTA) is recommended.
The HEART Pathway combines the HEART score with serial high-sensitivity troponin measurements. At 0 hours and 3 hours (or 0 and 1 hour with rapid hs-troponin), patients with HEART ≤3 and negative troponins are classified as low risk and eligible for discharge. This protocol has been shown to reduce hospitalizations by 20% and reduce healthcare costs by $1,200 per patient without increasing adverse events.
Successful HEART score implementation requires ED-wide education, embedded EMR tools, and clear pathways for outpatient follow-up. Common barriers include physician discomfort with early discharge, lack of rapid outpatient stress testing access, and medicolegal concerns. Structured implementation with departmental buy-in overcomes these barriers.
The HEART score has limited validation in populations under 30, patients with left bundle branch block (which makes ECG interpretation difficult), patients on chronic anticoagulation, and those with end-stage renal disease (elevated baseline troponin). Clinical judgment should override the score in presentations with high clinical concern regardless of HEART score.
The HEART Pathway trial showed that patients with HEART ≤3 AND two negative troponins (0h and 3h) had a 30-day MACE rate of <2%. These patients can be safely discharged with outpatient follow-up, typically including stress testing within 72 hours. This approach is endorsed by multiple professional societies.
Score 0 for atypical features (pleuritic, positional, reproducible). Score 1 for mixed features. Score 2 for classic ACS features: substernal pressure, radiation to arm/jaw, diaphoresis, exertional, response to nitroglycerin. The history assessment is the most subjective component and has the lowest inter-rater reliability.
Serial troponins (0h and 3h, or 0h and 1h with high-sensitivity assays) are essential. A rising pattern (delta troponin) is more specific for MI than absolute levels. The HEART pathway specifically requires negative serial troponins for safe low-risk classification.
TIMI was developed for confirmed ACS, while HEART was designed for undifferentiated ED chest pain. HEART has better sensitivity (~96-99%) for identifying truly low-risk patients. TIMI classifies more patients as moderate/high risk, leading to more admissions without improving outcomes. HEART is preferred for ED risk stratification.
Yes. HEART has been validated with both conventional and high-sensitivity troponin assays. With hs-troponin, the 0h/1h algorithm can be combined with HEART for faster triage. Some centers use HEART ≤3 + hs-troponin <52 ng/L as rapid discharge criteria.
Standard cardiovascular risk factors: hypertension, hyperlipidemia, diabetes, current smoking, obesity (BMI >30), family history of premature CAD, and known atherosclerotic disease (prior MI, PCI, CABG, stroke, PAD). Score 2 if ≥3 factors present or known atherosclerosis.